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Colorado State University, 1619 Campus Delivery, FortSelf-splicing of group I intron from the 26S rRNA of Candida albicans is essential for maturation of
the host RNA. Here, we demonstrated that the co-transcriptional splicing of the intron in vitro was
blocked by antisense oligonucleotides (AONs) targeting the P3–P7 core of the intron. The core-tar-
geted AON effectively and speciﬁcally inhibited the intron splicing from its host RNA in living C. albi-
cans. Furthermore, ﬂow cytometry experiments showed that the growth inhibition was caused by a
fungicidal effect. For the ﬁrst time, we showed that an AON targeting the ribozyme core folding spe-
ciﬁcally inhibits the endogenous ribozyme splicing in living cells and speciﬁcally kills the intron-
containing fungal strains, which sheds light on the development of antifungal drugs in the future.
 2009 Federation of European Biochemical Societies. Published by Elsevier B.V. All rights reserved.1. Introduction ing the continuous strand of the P3–P7 core speciﬁcally inhibit theGroup I intron is a class of catalytic RNA whose self-splicing is
essential for maturation of host RNAs and ultimately for the
growth of host organisms [1]. The probability of targeting group I
introns for antimicrobial therapeutics was initially assessed about
ﬁfteen years ago [2]. Although a number of antibiotics efﬁciently
inhibit the ribozyme activity in vitro, they preferentially inhibit
bacterial and mitochondrial translation when get into cells [3–5].
In this study, we aimed to address the question by using anti-
sense oligonucleotide (AON) to target a group I ribozyme located
in the 26S rRNA gene of C. albicans. The highly conserved core
structure of group I introns contain the P3–P7 and P4–P6 domains
that are assembled to a compact structure by two adjacent J6/7:P4
and J3/4:P6 base triples [6,7]. The P3–P7 core region contains the
catalytically active site, and represents the most essential structure
of all group I introns [7]. During transcription of the Candida group
I ribozyme, synthesis of the later strands of P3 and P7 helices is 141
nt and 44 nt slower than synthesis of the early strands, respectively
(Fig. 1A). This presumably makes the P3–P7 pseudoknot highly
susceptible to be targeted by antisense oligonucleotides. In this
study, we unambiguously showed that the unmodiﬁed AONs pair-chemical Societies. Published by E
munology and Pathology,
Collins, CO 80523, USA.splicing of the Candida group I intron in vivo and a 20-OMe modi-
ﬁed AON yielded an IC50 of 2.3 lM. We further demonstrated that
IC50 of the growth inhibition by the same 20-OMe modiﬁed AON
was 4.8 lM. This study validates that the group I ribozyme can
be speciﬁcally targeted in vivo to develop new antimicrobial
treatments.
2. Materials and methods
2.1. Assay of IC50 of the P3–P7 core-targeted AONs
A 608 nt rRNA precursor containing the Candida intron [8] was
transcribed in vitro in the presence of six units of T7 RNA polymer-
ase, 500 lM of rATP, rCTP and rUTP, 100 lM rGTP and 0.01 lCi
[a-32P] GTP (3000 Ci/mmol), as well as varying concentrations of
the P3–P7 core-targeted AONs for 60 min. The inhibitory effect of
each AON on the ribozyme self-splicing was determined and plot-
ted by equation
½Y ¼ Bottomþ ðTop—BottomÞ=ð1þ 10^ððLogIC50-XÞ HillSlopeÞÞ:2.2. Fluorescence microscopy Imaging
C. albicans was diluted into YNB (yeast extract nitrogen base)
medium to an initial OD540 of 0.1 in the presence of 25 lM of thelsevier B.V. All rights reserved.
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harvested cells were treated as previously reported [9]. Finally, a
BX-60 confocal ﬂuorescence microscope (Olympus, Japan) was
used to examine the specimens.
2.3. RT-PCR analysis of the Candida intron splicing in C. albicans
C. albicans cells treated with AONs were harvested by centrifug-
ing at 5000g for 2 min. The supernatants were discarded, and aFig. 1. (A) The secondary structure of the Candida group I ribozyme. The P3–P7 core
is shaded and indicated using the gray and large font. The continuous sequence of
the P3–P7 core-targeted by AONs is labeled in the bold italic font, and the 50-30
direction of the AON sequences is labeled as a big arrow. (B) Inhibition of the self-
splicing of the Candida ribozyme during in vitro transcription by the 20-OMe
modiﬁed 240–261R. One representative gel is shown in the upper panel, and the
spliced fraction of the ribozyme RNA under varying concentrations of 20-OMe
modiﬁed 240–261R is plotted by ﬁtting to a curve Y = Bottom + (Top–Bottom)/
(1 + 10^((LogEC50-X))).100 ll of lysis mixture including 1 M sorbitol, 0.1 M EDTA (pH
8.0), 0.1% b-mercaptoethanol and 50 units of lyticase was added
to lyse the collected C. albicans cells. The lysates were incubated
at 30 C for 20 min and the debris was removed by a 2-min centri-
fugation. The supernatants were mixed with 200 ll complete buf-
fer and 400 ll phenol-chloroform, vibrated for 90 s, and
centrifuged at 12,000g for 10 min. The aqueous phase was trea-
ted with RQ1 DNase (Promega) for 60 min. 1 lg total RNA was re-
verse-transcribed and Candida ribozyme precursor RNA and PGK
mRNA levels were determined by semi-quantitative PCR. Primers
were
Ca2158: 50-TAATACGACTCACTATAGGGAATTAAAACATAGCATT-
GTGATG-30
Ca2386: 50-GGCTGTGGTTTCGCTAGAT-30
Intron 50T7: 50-TAATACGACTCACTATAGGCAACCCACAAGG-
GAGGCAAA-30
PGK-F: 50-AGCGATTATCAATTGCAGAAG-30
PGK-R: 50-TGGTATCTCAAGTTTTCCAAC-30
2.4. Assay of AON inhibition of C. albicans growth on Petri dish
C. albicans was grown at 30 C in YNB liquid medium (pH 3)
with a starting OD540 of 0.01. When cell density reached about
OD540 of 1, serial dilutions of cultures were prepared in fresh
YNB liquid medium containing the indicated concentrations of
unmodiﬁed or 20-OMemodiﬁed (Darhmarcon, Lafayette, CO) AONs.
The diluted cells were then spotted onto YPD (yeast extract pep-
tone dextrose) plate, and growth was assessed after overnight
incubation at 37 C.
2.5. Flow cytometry analysis
Clinically isolated C. albicans strains 4-1 and 62-1 were kindly
provided by G. Lemay (University of Montreal, Montreal, Canada).
Nine other C. albicans clinical isolates were kindly provided by G.
St-Germain (Laboratoire de Santé Publique du Québec, Quebec,
Canada). C. albicans cells treated with 5 lM of FITC-labeled 20-
OMe 240-261R at 37 C for 8 h were centrifuged at 5000g for
2 min and rinsed twice with 1 ml PBS, then resuspended in
800 ll of PBS for ﬂow cytometry analysis. Brieﬂy speaking, PI (pro-
pidium iodide) binds to dead cells that have ruptured membranes,
living cells were not labeled with PI [10,11]. The FITC and PI ﬂuo-
rescence signals were determined using a FACScan ﬂow cytometer
(Beckman Coulter) and analyzed using EXPO32ADC software. The
mortality rate of cells with the FITC-labeled AON uptake was calcu-
lated from the following formula. Mortality rate = Quadrant II/
(Quadrant I + Quadrant II). The data were plotted using the Graph-
Pad Prism 4.0 program.Table 1
IC50 values and the maximal inhibitions of a series of AONs targeting the P3–P7 core.
Co-transcriptional splicing was conducted in the presence of varying concentrations
of each AON as described in Fig. 1B. Two sets of experiments for each AON (the name
of the AON indicates the position on the intron where it binds to) were analyzed by
GraphPad Prism 4.0 and shown here.
AON IC50 (lM) Maximal inhibition
236–262R 0.3794 90.2%
237–262R 0.3020 94.6%
238–262R 0.3166 94.1%
239–262R 0.3579 85.5%
240–262R 0.3516 92.8%
239–260R 0.3033 94.4%
242–260R 0.2874 99.1%
235–265R 0.1792 99.0%
Fig. 2. The effects of the P3–P7 core-targeted AONs on splicing of the endogenous
Candida group I intron in vivo. (A) Confocal ﬂuorescence microscopy analysis of the
AON uptake in the intron-containing (4-1) and intronless (62-1) C. albicans strains,
respectively. (B) RT-PCR analysis of the P3–P7 core-targeted AON inhibition of
intron splicing in C. albicans cells. RNA level of 3-phosphoglycerate kinase gene
(PGK) was ampliﬁed as a loading control. Intron–exon RNA indicates the unspliced
precursor rRNA in the intron-containing strain, and the exon–exon RNA indicates
the rRNA that was only ampliﬁed for the intronless C. albicans samples. (C) RT-PCR
analysis of the dose-dependent inhibition of the intron splicing in the intron-
containing C. albicans 4-1 strain. More details of the experiments and one
representative gel are shown in Supplementary Fig. S1. The increase in the
unspliced precursor RNA (intron–exon) by the AON treatment was measured in this
assay. We set the maximal increase at 50 lM of 20-OMe 240–261R as one, which is
coined as maximal inhibition of splicing. The relative inhibitions at other AON
concentrations were obtained accordingly and plotted against the AON concentra-
tion by ﬁtting Y = Bottom + (Top–Bottom)/(1 + 10^((LogEC50-X))).
Fig. 3. The P3–P7 core-targeted AONs speciﬁcally inhibit the growth of the intron-
containing C. albicans strain. (A) Series of culture dilutions (dilution factor: 5) of the
C. albicans 4-1 and 62-1 strains treated with different unmodiﬁed or modiﬁed P3–
P7 core-targeted AON. (C) Dose-dependent growth inhibition. IC50 of 20-OMe
modiﬁed 240–261R in inhibiting the growth of C. albicans was determined by
plotting the percentage of growth at each concentration of 20-OMe modiﬁed 240–
261R relative to the control receiving no AON. The curve was ﬁt to Y = Bot-
tom + (Top–Bottom)/(1 + 10^((LogEC50-X))). One of the growth data is shown in
Supplementary Fig. S3.
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In vitro co-transcriptional splicing activity of the Candida ribo-
zyme was measured to select the sensitive target sequence of
AONs on the ribozyme. We found that all AONs pairing most or
the entire continuous strand of the P3–P7 core achieved their
half-maximal inhibition of the co-transcriptional splicing of the
Candida intron at about 0.3 lM concentration (Fig. 1A and Table
1). Fig. 1B shows that 20-OMe AON target this region reached the
half-maximal splicing inhibitory effect at 37 nM, while most of
AONs pairing other regions of the intron did not inhibit or only
slightly inhibited the intron splicing (data not shown). These dataare consistent with our recent ﬁnding that formation of P3–P7 core
is slow during co-transcriptional folding (unpublished, L. Zhang
and Y. Zhang), and therefore represents the most effective struc-
ture for antisense interruption of the active ribozyme folding.
However, it appears that the inhibition can only be effective
when the antisense oligonucleotides are sufﬁciently long to pairing
the continuous segment comprising J6/7, P7 and P30 of the P3–P7
core (Table 1 and data not shown). Consistently, a previous study
have shown that the short AONs only this region did not inhibit
the co-transcriptional splicing of the intron at up to 100 lM con-
centration [12].
C. albicans has been reported to efﬁciently take up oligonucleo-
tides from growth medium [9]. As shown in Fig. 2A, confocal ﬂuo-
rescence microscope showed that the AON was distributed
throughout the C. albicans cell including nucleus where intron
splicing occurs regardless of the presence or absence of the group
I intron. We then examined whether the AON uptaken into the nu-
cleus of C. albicans inhibited the splicing of the endogenous Candida
group I intron in vivo. Here, both the unmodiﬁed and 20-OMe mod-
iﬁed AONs were used to assess their ability in inhibition of intron
splicing in living C. albicans cells. Fig. 2B showed that 2 lM of the
unmodiﬁed AON 240–261R in growth medium substantially ele-
vated the level of the unspliced precursor rRNA resulted from an
inhibition of the intron splicing. Some other unmodiﬁed AONs tar-
geting the P3–P7 core also effectively increased the level of the
precursor rRNA (data not shown). In contrast, 2 lM of AON 299–
320R targeting the P9 region of the intron did not change the level
of the precursor rRNA at all (Fig. 2B). Fig. 2C and Supplementary
Fig. S1 show that 20-OMe 240–261R effectively inhibited the splic-
ing of the Candida group I intron from its host rRNA precursor at a
Fig. 4. Flow cytometry analysis of AON-induced cell death in eleven clinically
isolated C. albicans strains. The FITC-labeled and 20-OMe modiﬁed 240–261R at
5 lM was used in each analysis. (A) Flow cytometry analysis of AON-induced cell
death in 4-1 and 62-1 strains. The intensities of the ﬂuorescein signals for FITC and
propidium iodide (PI) emitted from a population of cells were shown on the Y-axis
and X-axis, respectively. (B) Analysis of the AON-induced mortality of all eleven
clinical C. albicans isolates. For each strain, the ratio of cells that took up the
ﬂuorescence antisense oligonucleotide (Quadrant I + Quadrant II) to the total cells
(sum of four Quadrants) was calculated. The fraction of dead cells among the cells
with AON uptake was determined as Mortality = Quadrant II/(Quadrant I + Quad-
rant II). (C) The correlation between the oligo uptake and the cell death among the
intron-containing strains. The cell ratios of dead/total were plotted against Oligo-
uptake/Total using a linear regression analysis.
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obtained at a culture medium concentration of 2.3 lM.
Because assembly of the intron-containing rRNA into the large
ribosome subunit prevents its association with the small ribosome
subunit [13], we predicted that the presence of the increased level
of intron-containing 26S rRNA precursor may be toxic to the in-
tron-containing cells, and that the growth of intron-containing
but not the intronless C. albicans strains would be inhibited by
the P3–P7 core-targeted AON. Supplementary Fig. S2 shows that
the core-targeted AONs and pentamidine speciﬁcally inhibitedthe growth of the intron-containing but not the intronless C. albi-
cans strain, but the same concentration of the control AON
299–320R did not inhibit the growth of either C. albicans strain.
Moreover, 5 lM of 20-OMe modiﬁed 240–261R yielded a similar
inhibition as that of 25 lM of the unmodiﬁed counterpart
(Fig. 3A), demonstrating the enhanced binding activity of the
AON by 20-OMe modiﬁcation. Fig. 3B and Supplementary Fig. S3
show that 20 OMe 240–261R dose-dependently inhibited the
growth of the intron-containing C. albicans strain, and the half-
maximal inhibition (IC50) was achieved at a concentration of
4.77 lM, equivalent to that of the inhibition of the intron splicing
in vivo (2.3 lM). We therefore conclude that blocking the intron
splicing from the 26S rRNA precursor of C. albicans cells by 20-
OMe modiﬁed AONs targeting the P3–P7 core effectively inhibits
the cell growth.
Flow cytometry experiments were further carried out to exam-
ine whether the observed growth inhibition is resulted from a fun-
gicidal or fungistatic mechanism. FITC-labeled and 20-OMe
modiﬁed 240–261R was used to sort the cell population that had
taken up the AON (Quadrants I and II), and propidium iodide stain-
ing to sort the dead cells (Quadrants II and IV) (Fig. 4A). Shift of the
cell population from Quadrant III to both Quadrants I and II upon
the addition of the labeled AON indicates AON uptake, and the
Quadrant II speciﬁcally represents dead population resulted from
the AON uptake. Remarkably, Fig. 4A shows that, upon the treat-
ment by 5 lM FITC-labeled 240–261R, a signiﬁcant shift to Quad-
rant II was only observed in intron-containing C. albicans strain
4-1, but not evident in the intronless strain 62-1. The effect of
the FITC-labeled 240–261R on the viability of a total of eight in-
tron-containing and three intronless independent C. albicans iso-
lates was further examined. It is shown that the AON uptake
differed signiﬁcantly among different isolates regardless of the
presence of the Candida group I intron (Fig. 4B). However, when
the percentage of dead cells in Quadrants II was normalized to
the total cell population with AON uptake (Quadrants I and II),
we found that 30–50% cells with AON uptake was dead in all eight
intron-containing strains, but only 4% background cell mortality
in the AON uptake population was observed for all three intronless
strains (Fig. 4B).
Counteracting microbial infections by antisense therapeutics
has been widely studied [14–16]. In this work, we demonstrated
that a 20-OMe modiﬁed antisense oligonucleotide 240–261R that
interrupts the P3–P7 core folding speciﬁcally and efﬁciently inhib-
its the in vivo splicing of the endogenous group I intron from the
26S rRNA precursor of C. albicans, as well as the growth of the in-
tron-containing C. albicans strain. We are aware that the Candida
group I intron is present in about 40% of the clinically isolated C.
albicans strains, which may prevent a wide use of this approach
in combating all C. albicans infections. Nonetheless, the high spec-
iﬁcity of the P3–P7 core-targeted AON therapy provides a valuable
alternative in controlling C. albicans infections. Moreover, a similar
intron was found in all the studied Candida dubliniensis, another
Candida pathogen causing signiﬁcant clinical problem [17], and
thus the P3–P7 core-targeted AON approach may be applicable to
against C. dubliniensis infection. Furthermore, if slow folding of
the P3–P7 core in vivo is general for all group I introns, anti-
sense-targeting the core formation could be extended to kill Pneu-
mocystis carinii and other pathogenic microbes containing a group I
intron in their essential genes.
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